| Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067) (NCT01844505) | Bristol-Myers Squibb | 2013-06-11 |
| Pharmacokinetics, Safety and Tolerability of Single-dose Belatacept in Adolescent Kidney Transplant Recipients (NCT01791491) | Bristol-Myers Squibb | 2013-05-09 |
| A Phase 1, Randomized, Double-Blind, Placebo-Controlled Escalating Single Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ND-L02-s0201 Injection in Normal Healthy Subjects (NCT01858935) | Bristol-Myers Squibb | 2013-05-01 |
| Effect of SAR302503 on ECG Activity in Patients With Solid Tumors (NCT01836705) | Bristol-Myers Squibb | 2013-05-01 |
| Study to Assess the Effect of BMS-791325 on the Pharmacokinetics of Midazolam in Healthy Subjects (NCT00996879) | Bristol-Myers Squibb | 2013-05-01 |
| Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064) (NCT01783938) | Bristol-Myers Squibb | 2013-04-30 |
| Abatacept Post-marketing Clinical Study in Japan (NCT01758198) | Bristol-Myers Squibb | 2013-04-11 |
| Effectiveness of Dasatinib in Adult Patients With Chronic Myeloid Leukemia in China: A Multicenter, Registry Study (NCT02389972) | Bristol-Myers Squibb | 2013-04-11 |
| Bioequivalence Study of Individual Atazanavir and Cobicistat Compared With Atazanavir in Fixed-dose Combination With Cobicistat (NCT01837719) | Bristol-Myers Squibb | 2013-04-01 |
| Methotrexate-Inadequate Response Autoinjector Device Sub Study (NCT01844895) | Bristol-Myers Squibb | 2013-04-01 |
| Safety and Efficacy Study in Subjects With Chronic HCV and Underlying Hemophilia (NCT01741545) | Bristol-Myers Squibb | 2013-03-31 |
| A Study in Maintenance Kidney Transplant Recipients Following Conversion to Nulojix® (Belatacept)-Based (NCT01820572) | Bristol-Myers Squibb | 2013-03-27 |
| Long-term Experience With Abatacept SC in Routine Clinical Practice (NCT02090556) | Bristol-Myers Squibb | 2013-03-26 |
| Study to Evaluate the Effects of BMS-813160 on Protein Loss in the Urine of Subjects With Type 2 Diabetes and Diabetic Kidney Disease (NCT01752985) | Bristol-Myers Squibb | 2013-03-18 |
| Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin (NCT01795911) | Bristol-Myers Squibb | 2013-03-01 |
| Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma (NCT01775631) | Bristol-Myers Squibb | 2013-03-01 |
| Phase 2b Study of BMS-986094 and Daclatasvir, With or Without Ribavirin for the Treatment of Patients With Chronic Hepatitis C (NCT01629732) | Bristol-Myers Squibb | 2013-03-01 |
| Safety and Efficacy Study of Peginterferon Lambda-1a vs. Peginterferon Alfa-2a, Plus Ribavirin in Subjects With Genotype 1 Hepatitis C (NCT01754974) | Bristol-Myers Squibb | 2013-03-01 |
| Study to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in Advanced Melanoma (NCT01709162) | Bristol-Myers Squibb | 2013-03-01 |
| Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis (NCT01766817) | Bristol-Myers Squibb | 2013-01-31 |
| An Observational Registry of Abatacept in Patients With Juvenile Idiopathic Arthritis (NCT01357668) | Bristol-Myers Squibb | 2013-01-30 |
| Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis (NCT01714817) | Bristol-Myers Squibb | 2013-01-22 |
| Study of Nivolumab (BMS-936558) Compared With Dacarbazine in Untreated, Unresectable, or Metastatic Melanoma (NCT01721772) | Bristol-Myers Squibb | 2013-01-18 |
| Study to Evaluate a Single Dose of Apixaban in Pediatric Participants at Risk for a Thrombotic Disorder (NCT01707394) | Bristol-Myers Squibb | 2013-01-10 |
| Efficacy and Safety Evaluation of a Regimen Consisting of Peginterferon Lambda-1a + Ribavirin + Daclatasvir (Lambda + RBV + DCV) in HCV Genotype 1b Treatment naïve Patients or Prior Relapsers to Peginterferon Alfa + Ribavirin (Alfa + RBV) Therapy (NCT01718158) | Bristol-Myers Squibb | 2013-01-01 |
| Study to Evaluate Effect of Belatacept on Pharmacokinetics of Inje Cocktail in Healthy Volunteers (NCT01766050) | Bristol-Myers Squibb | 2013-01-01 |
| A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037) (NCT01721746) | Bristol-Myers Squibb | 2012-12-21 |
| Safety Study of BMS-986015 (Anti-KIR) in Combination With Ipilimumab in Subjects With Selected Advanced Tumor (NCT01750580) | Bristol-Myers Squibb | 2012-12-01 |
| Open Label Pharmacokinetic Study of SAR302503 in Subjects With Hepatic Impairment (NCT01762462) | Bristol-Myers Squibb | 2012-12-01 |
| Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib (NCT01660906) | Bristol-Myers Squibb | 2012-12-01 |
| Effectiveness of Nucleos(t)Ide Analogs (NUC) Therapy Among Naive CHB Patients in China (NCT01726439) | Bristol-Myers Squibb | 2012-12-01 |
| Safety Sudy of Atazanavir Boosted With Ritonavir in the Treatment of HIV Infection in Pediatric Patients (NCT01691794) | Bristol-Myers Squibb | 2012-11-30 |
| Study of Nivolumab (BMS-936558) in Patients With Advanced or Metastatic Squamous Cell Nonsmall-cell Lung Cancer Who Have Received At Least 2 Prior Systemic Regimens (NCT01721759) | Bristol-Myers Squibb | 2012-11-16 |
| Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma (NCT01696045) | Bristol-Myers Squibb | 2012-11-12 |
| Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLC (NCT01673867) | Bristol-Myers Squibb | 2012-11-02 |
| Phase 2 Study in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly (NCT01692366) | Bristol-Myers Squibb | 2012-11-01 |
| A Phase 3, Comparative Study of Asunaprevir and Daclatasvir Combination Therapy Versus Telaprevir Therapy in Japanese HCV Subjects (NCT01718145) | Bristol-Myers Squibb | 2012-11-01 |
| Study of the Pharmacokinetics and Safety of Asunaprevir in Patients With Kidney Disease (NCT01886599) | Bristol-Myers Squibb | 2012-11-01 |
| A Safety Study of BMS-852927 in Subjects With Hypercholesterolemia (NCT01651273) | Bristol-Myers Squibb | 2012-11-01 |
| Open Label Pharmacokinetic Study of SAR302503 in Subjects With Renal Impairment (NCT01763190) | Bristol-Myers Squibb | 2012-11-01 |
| A Follow-up Evaluation for Safety in Subjects Who Participated in a Phase 1 Study With BMS-986094 (INX-08189) (NCT01732848) | Bristol-Myers Squibb | 2012-11-01 |
| An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer (NCT01658878) | Bristol-Myers Squibb | 2012-10-30 |
| Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017) (NCT01642004) | Bristol-Myers Squibb | 2012-10-16 |
| Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors (NCT01653470) | Bristol-Myers Squibb | 2012-10-12 |
| Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025) (NCT01668784) | Bristol-Myers Squibb | 2012-10-09 |
| A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors (NCT01714739) | Bristol-Myers Squibb | 2012-10-07 |
| Phase 2 Study of Ipilimumab Plus Dacarbazine in Japanese Patients With Advanced Melanoma (NCT01681212) | Bristol-Myers Squibb | 2012-10-01 |
| PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma (NCT01621490) | Bristol-Myers Squibb | 2012-09-27 |
| Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma (NCT01673854) | Bristol-Myers Squibb | 2012-09-13 |
| Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib (NCT01593254) | Bristol-Myers Squibb | 2012-09-12 |
| Pharmacokinetic Study of BMS-914143 in Participants With Normal Renal Function and Mild, Moderate, Severe and End-stage Renal Dysfunction (NCT01708889) | Bristol-Myers Squibb | 2012-09-01 |
| Pharmacokinetic and Safety Study of Daclatasvir in Patients With Renal Impairment (NCT01830205) | Bristol-Myers Squibb | 2012-09-01 |
| Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer (NCT01611558) | Bristol-Myers Squibb | 2012-08-21 |
| An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma (NCT01592370) | Bristol-Myers Squibb | 2012-08-02 |
| Open-Label Study Comparing Efficacy and Safety of ATV/RTV+3TC With ATV/RTV+TDF/FTC in HIV-Infected, Treatment Naïve Subjects, Followed by Treatment With ATV/RTV+3TC (NCT01620944) | Bristol-Myers Squibb | 2012-07-31 |
| Multiple Ascending-Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BMS-933043 in Healthy Subjects (NCT01605994) | Bristol-Myers Squibb | 2012-07-01 |
| Study of Daclatasvir (BMS-790052) and Simeprevir (TMC435) in Patients With Genotype 1 Chronic Hepatitis C Virus (NCT01628692) | Bristol-Myers Squibb | 2012-07-01 |
| Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3 (NCT01616524) | Bristol-Myers Squibb | 2012-07-01 |
| An Efficacy Study in Gastric and Gastroesophageal Junction Cancer Comparing Ipilimumab Versus Standard of Care Immediately Following First Line Chemotherapy (NCT01585987) | Bristol-Myers Squibb | 2012-07-01 |
| A Two-Part, Phase 1, Single-Dose Study of IL-31 mAb (Anti-Interleukin 31 Monoclonal Antibody); in Healthy Subjects and Adults With Atopic Dermatitis (NCT01614756) | Bristol-Myers Squibb | 2012-07-01 |
| Safety and Efficacy Study of BMS-823778 to Treat Uncontrolled High Blood Pressure in Overweight and Obese Patients (NCT01602367) | Bristol-Myers Squibb | 2012-07-01 |
| Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer (NCT01471197) | Bristol-Myers Squibb | 2012-07-01 |
| Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone (NCT01605084) | Bristol-Myers Squibb | 2012-06-30 |
| Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir (NCT01598090) | Bristol-Myers Squibb | 2012-06-14 |
| Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE) (NCT01838512) | Bristol-Myers Squibb | 2012-06-13 |
| A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma (NCT01511913) | Bristol-Myers Squibb | 2012-06-03 |
| Safety Study of IL-21/Anti-PD-1 Combination in the Treatment of Solid Tumors (NCT01629758) | Bristol-Myers Squibb | 2012-06-01 |
| Drug Interaction Study of SAR302503 in Patients With Solid Tumor (NCT01585623) | Bristol-Myers Squibb | 2012-06-01 |
| Trial of Dasatinib in Patients With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation (NCT01514864) | Bristol-Myers Squibb | 2012-05-31 |
| Safety Study of Elotuzumab in Combination With Thalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (NCT01632150) | Bristol-Myers Squibb | 2012-05-01 |
| Single Ascending Dose Safety Study of BMS-962476 in Healthy Subjects and Patients With Elevated Cholesterol on Statins (NCT01587365) | Bristol-Myers Squibb | 2012-05-01 |
| Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials) (NCT01573351) | Bristol-Myers Squibb | 2012-05-01 |
| Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects: Part A: Safety and Efficacy of INX-08189 With Peg IFN Alfa-2a and Ribavirin. Part B: INX-08189 in Interferon Free Treatment With Daclatasvir and/or Ribavirin (NCT01425970) | Bristol-Myers Squibb | 2012-05-01 |
| Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives) (NCT01581203) | Bristol-Myers Squibb | 2012-05-01 |
| Phase II, Open Label, Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With Ruxolitinib (NCT01523171) | Bristol-Myers Squibb | 2012-04-30 |
| Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia (NCT01460160) | Bristol-Myers Squibb | 2012-04-13 |
| Multiple Ascending Dose Study of BMS-929075 in Hepatitis C Virus (HCV) Infected Patients (NCT01525212) | Bristol-Myers Squibb | 2012-04-01 |
| Belatacept in Renal Transplantation: Analyses Using Data From the Collaborative Transplant Study (NCT01471223) | Bristol-Myers Squibb | 2012-03-31 |
| Patterns of Use of Belatacept: Analysis of Data From the Collaborative Transplant Study (NCT01476943) | Bristol-Myers Squibb | 2012-03-31 |
| Safety and Efficacy Study of Pegylated Interferon Lambda Versus Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C (NCT01447394) | Bristol-Myers Squibb | 2012-03-01 |
| Determine the Pharmacokinetics and Safety of Brivanib in Chinese Subjects With Advanced Primary Liver Cancer (Hepatocellular Carcinoma: HCC) (NCT01540461) | Bristol-Myers Squibb | 2012-03-01 |
| Three-year Follow-up Study of Subjects Who Participated in a Previous Lambda (BMS-914143) Chronic Hepatitis C Clinical Trial (NCT01525810) | Bristol-Myers Squibb | 2012-03-01 |
| Japanese Phase 1 Multiple Ascending Dose Study (NCT01515202) | Bristol-Myers Squibb | 2012-03-01 |
| Evaluating Nulojix (Belatacept) Long-Term Safety in Transplant (NCT01386359) | Bristol-Myers Squibb | 2012-02-29 |
| Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab (NCT01515189) | Bristol-Myers Squibb | 2012-02-17 |
| Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016) (NCT01472081) | Bristol-Myers Squibb | 2012-02-09 |
| Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial (NCT01492504) | Bristol-Myers Squibb | 2012-02-07 |
| Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease (NCT01492374) | Bristol-Myers Squibb | 2012-02-01 |
| Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (NCT01471210) | Bristol-Myers Squibb | 2012-02-01 |
| Assessment of Blood Glucose Changes in Healthy Volunteers After BMS-754807 Alone or BMS-754807 With Metformin (NCT01525823) | Bristol-Myers Squibb | 2012-02-01 |
| Pattern Of Use Of Belatacept In US Transplant Recipients (NCT01670058) | Bristol-Myers Squibb | 2012-01-31 |
| Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Various Levels of Renal Function (NCT01393964) | Bristol-Myers Squibb | 2012-01-06 |
| Study Comparing Daclatasvir (BMS-790052) With Telaprevir Combined With Peginterferon Alfa-2a and Ribavirin in Patients With Chronic Hepatitis C Virus Infection (NCT01492426) | Bristol-Myers Squibb | 2012-01-01 |
| A Phase 3 Study in Combination With BMS-790052 and BMS-650032 in Japanese Hepatitis C Virus (HCV) Patients (NCT01497834) | Bristol-Myers Squibb | 2012-01-01 |
| Oral Anticoagulant Discontinuation, Adherence Patterns, Hospitalizations and Costs in Non-Valvular Atrial Fibrillation (NVAF) Patients (NCT02792335) | Bristol-Myers Squibb | 2012-01-01 |
| Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis (NCT01437787) | Bristol-Myers Squibb | 2011-12-31 |
| Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma (NCT01441973) | Bristol-Myers Squibb | 2011-12-28 |
| Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012) (NCT01454102) | Bristol-Myers Squibb | 2011-12-16 |
| Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone (NCT01450761) | Bristol-Myers Squibb | 2011-12-13 |
| Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma (NCT01489059) | Bristol-Myers Squibb | 2011-12-01 |